A single-use bioreactor, a bioreactor with a disposable bag instead of a culture vessel. Single-use bioreactors allow processors to implement disposable technology, such as single-use bags, in manufacturing process steps that have previously been reserved for stainless steel equipment. It is widely used in the field of mammalian cell culture and is now rapidly replacing conventional bioreactors. Due to the utilization of pre-sterilized bioprocess bags, they greatly reduce the additional time and cost of sterilization, and also, maintenance cost is less. A single-use bioreactor is highly used in biopharmaceutical processes. This is directly linked to their unique/latest ability to reduce investment, enhance flexibility and limit operational costs.
The global Single-Use bioreactors market is expected to gain considerable growth over the forecasting period from 2020-2027. The major factors are the growing demand in pharmaceutical and biopharmaceutical industries and the increasing use of mammalian cell culture. Additionally, the increasing utilization of single-use bioreactors for various processes, including process development, process optimization, media preparation, cell cultivation, and microbial processes in R&D, will spur the global Single-Use bioreactors market in the future periods. Also, the single-use bioreactors enhance the biological & safety process and reduce the risk of cross-contamination. It is highly suitable for biopharmaceutical products to robust cell growth due to the advantages including high maintenance, low detergent cost, and saves on pharmaceutical manufacturing energy.
Moreover, the upsurge in demand for single-use bioreactors for applications including microbial fermentation, mammalian cell culture, clinical trials for drugs, and large-scale commercial biomanufacturing fuel the demand for single-use bioreactors in the medicine market. Furthermore, the rapidly expanding R&D activities at the academic and industrial level and increasing scope of product innovation are expected to witness the growth of single-use bioreactors in the upcoming years. However, the repetitive purchase for consumables and high disposal cost is the restraint of the technology. However, increasing demand in the production of different drugs with high quality propels the growth of the single-use bioreactors market across the globe.
Single-use and continuous upstream processes have proven to be cost-efficient options to increase biomass production. It also eliminates the cleaning and sterilization process and the reduction of installation and support systems. This advantage benefits a manufacturer to purchase more capacity for a limited budget. Additionally, Single-use bioreactors provide better performance with the wide acceptance of bioprocess bags than traditional stainless steel bioreactors. Recent advances in technology supporting biopharmaceutical production and highly adopted in the production of human & veterinary vaccines, mAbs proteins, and gene therapy vectors.
Based on the product type, the global Single-use bioreactors market is segregated into systems, media bags, filtration assemblies, and other products. The system segment is estimated to witness the highest growth over the analysis timeframe due to the rise in adoption of single-use technology, lower investment, and & time-efficient and highly adopted applications such as the development of a new drug, vaccines, cell culture, biofuels, and antibodies.
The filtration assemblies or fermenters will grow significantly due to the high demand in industrial microbiology with efficient temperature control, mixing, and mass transfer.
The global Single-use bioreactors market is categorized/divided into stirred and rocking (motion) single-use bioreactors based on the technology. The rocking single-use bioreactors segment held for a significant market share in 2019 and will gain maximum market revenue by 2027 due to non-contamination from impeller during mixing, no cleaning or sterilization requirement, and less likely to damage cells as compared to stirred tanks.
The global Single-use bioreactors market is classified into mammalian cells, bacteria, yeast, and other cell types based on the cell type. The mammalian segment is expected to be the highest revenue share for Single-use bioreactors during the forecasting period. The segment’s growth is primarily responsible for the growing use of viral vaccines and therapeutics protein.
The bacterial cell segment will witness a lucrative growth rate in the estimated period.
Based on the end-user, the global Single-use bioreactors market is segmented into pharmaceutical & biopharmaceutical companies, contract research organizations & contract manufacturing organizations, academic institutions, and research institutes. The CROs and CMOs segment will dominate the global Single-use bioreactors market by 2027. It is due to the surge in the outsourcing of R&D facilities for the pharmaceutical and biopharmaceutical industries.
The pharmaceuticals and biotechnology companies were nominated for the huge share of the Single-use bioreactors market in 2019 because of the increasing use in clinical trials and new drugs.
By geography, the global Single-use bioreactors market is segmented into North America, Europe, Europe, Asia Pacific, and The Middle East & Africa. North America is estimated to project significant’ growth over 2020-2026 due to advents in technology, the presence of leading industry players using innovative bioreactor & products, and increasing healthcare expenditure.
The Asia Pacific will capture a definite share of the Single-use bioreactors market by 2027. It is due to the increasing CMO with the capabilities of manufacturing vaccines and therapeutics.
Companies such as ABEC Inc, Merck KGaA, Danaher Corporation, Sartorius Stedim Biotech, Merck Millipore, Thermo Fisher Scientific, Celltainer, OmniBRx Biotechnologies, GE Healthcare, Pall Corporation, Sartorius AG, Eppendorf AG, and Distek Inc are the key players or the competitors in the global Single-use bioreactors market.
By Product Type
By Cell Type